← Back to Screener
Biohaven Ltd. (BHVN)
Price$11.43
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-1.60%
Price vs S&P 500 (4W)9.36%
VGM Score53.49
Market Capitalization$1.66B
All Metrics
Book Value / Share (Quarterly)$0.86
P/TBV (Annual)44.49x
Cash Flow / Share (Quarterly)$-3.95
Price vs S&P 500 (YTD)-13.41%
EPS (TTM)$-5.67
10-Day Avg Trading Volume2.85M
EPS Excl Extra (TTM)$-5.67
EPS (Annual)$-6.86
ROI (Annual)-253.92%
Cash / Share (Quarterly)$2.31
ROA (Last FY)-163.66%
EBITD / Share (TTM)$-5.41
ROE (5Y Avg)-487.22%
Cash Flow / Share (Annual)$-4.60
P/B Ratio12.80x
P/B Ratio (Quarterly)9.83x
Net Income / Employee (Annual)$-2,696,400
Net Interest Coverage (TTM)-27.53x
ROA (TTM)-138.00%
EPS Incl Extra (Annual)$-6.86
Current Ratio (Annual)3.18x
Quick Ratio (Quarterly)6.74x
3-Month Avg Trading Volume2.25M
52-Week Price Return-25.31%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.74
52-Week High$18.57
EPS Excl Extra (Annual)$-6.86
CapEx CAGR (5Y)-23.34%
Tangible BV CAGR (5Y)14.92%
26-Week Price Return14.33%
Quick Ratio (Annual)2.77x
13-Week Price Return-1.26%
Total Debt / Equity (Annual)4.59x
Current Ratio (Quarterly)7.41x
Enterprise Value$1.63B
Book Value / Share Growth (5Y)8.49%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.40
3-Month Return Std Dev77.09%
Net Income / Employee (TTM)$-2,363,800
ROE (Last FY)-1418.85%
EPS Basic Excl Extra (Annual)$-6.86
Total Debt / Equity (Quarterly)1.87x
EPS Incl Extra (TTM)$-5.67
ROI (TTM)-134.98%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.25
Price vs S&P 500 (52W)-53.51%
Year-to-Date Return-2.48%
5-Day Price Return16.51%
EPS Normalized (Annual)$-6.86
ROA (5Y Avg)-123.49%
Month-to-Date Return14.81%
Cash Flow / Share (TTM)$-6.72
EBITD / Share (Annual)$-6.83
LT Debt / Equity (Annual)4.59x
ROI (5Y Avg)-254.23%
LT Debt / Equity (Quarterly)1.87x
EPS Basic Excl Extra (TTM)$-5.67
P/TBV (Quarterly)11.45x
P/B Ratio (Annual)28.77x
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)-11.00%
Beta3.07x
Revenue / Share (TTM)$0.00
ROE (TTM)-450.00%
52-Week Low$7.48
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.88est. -0.84
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.04
4.04
4.04
4.04
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BHVNBiohaven Ltd. | — | — | C | $11.43 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Biohaven is a clinical-stage biopharmaceutical company developing treatments across immunology, neuroscience, and oncology. Its pipeline targets neuromuscular diseases, metabolic disorders, obsessive-compulsive disorder, and cancer, utilizing multiple therapeutic modalities including glutamate modulators, myostatin inhibitors, ion channel modulators, and antibody-drug conjugates. The company has multiple product candidates spanning these therapeutic areas at various development stages.